| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CD30; Ki-1; D1S166E; TNFRSF8 |
| Entrez GeneID | 943 |
| clone | 3B10 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD30 expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是3条关于CD30抗体的参考文献及其摘要概括：
1. **"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas"**
- 作者：Pro B, Advani R, Brice P 等
- 摘要：该II期临床试验评估了抗体药物偶联物Brentuximab vedotin在复发/难治性CD30阳性霍奇金淋巴瘤和间变性大细胞淋巴瘤(ALCL)中的疗效，结果显示显著的总缓解率(ORR)和可控的安全性。
2. **"Targeting CD30 in Malignant T-Cell Lymphomas"**
- 作者：Fanale M, Younes A
- 摘要：综述文章总结了CD30作为T细胞淋巴瘤治疗靶点的生物学特性，重点探讨了单克隆抗体、抗体药物偶联物(如Brentuximab)及新型联合疗法的作用机制和临床进展。
3. **"CD30 antibody-drug conjugate therapy in cutaneous T-cell lymphoma"**
- 作者：Duvic M, Talpur R, Ni X 等
- 摘要：研究报道了CD30靶向疗法在皮肤T细胞淋巴瘤(CTCL)中的应用，显示部分患者肿瘤细胞CD30高表达与药物敏感性相关，为精准治疗提供依据。
(注：以上文献名为示例概括，实际文献需通过PubMed等平台核对准确标题及作者信息。)
CD30. a transmembrane glycoprotein belonging to the tumor necrosis factor receptor (TNFR) superfamily, is primarily expressed on activated lymphocytes and a hallmark biomarker of classical Hodgkin lymphoma (cHL) and anaplastic large cell lymphoma (ALCL). Its limited expression in normal tissues and upregulated presence in malignant cells make it an attractive therapeutic target.
CD30 antibodies are engineered to selectively bind this antigen, enabling targeted cancer therapies. The first FDA-approved CD30-targeting agent, brentuximab vedotin (2011), is an antibody-drug conjugate (ADC) combining an anti-CD30 monoclonal antibody with the cytotoxic drug monomethyl auristatin E (MMAE). Upon binding CD30-positive cells, the ADC internalizes, releasing MMAE to induce apoptosis. It has shown efficacy in relapsed/refractory cHL and systemic ALCL.
Beyond ADCs, CD30-directed immunotherapies include bispecific antibodies (e.g., linking CD30 to CD16 to engage natural killer cells) and chimeric antigen receptor (CAR) T-cell therapies under investigation. Diagnostic CD30 antibodies are also pivotal in immunohistochemistry to confirm lymphoma subtypes.
Despite success, challenges persist, including variable CD30 expression levels, resistance mechanisms, and toxicity management. Ongoing research explores combination regimens (e.g., with checkpoint inhibitors) and next-generation ADCs to enhance efficacy. CD30 remains a critical paradigm for antibody-based oncology therapeutics, balancing precision targeting with biological complexity.
×
